Скачать или смотреть Amarin CEO John Thero on company’s FDA approval for key heart drug

Amarin CEO and president John Thero joins CNBC's "Power Lunch" team to discuss the drug company's FDA approval for Vascepa, a drug designed to reduce the incidence of heart attacks and strokes in high-risk patients. Amarin boosted its 2020 financial outlook following news of the approval.

Some doctors praise it to one of the most important advances in preventive cardiovascular care in the last 30 years, Thero said. The drug is expected to help millions of patients while charging a fraction of what other new drugs are introduced at in the past decade. Cost analysis shows that not only is it cost-effective but it would save society money by lowering and preventing costly heart attacks, Thero said.

For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://www.cnbc.com/pro/?__source=yo...

» Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision
» Subscribe to CNBC: https://cnb.cx/SubscribeCNBC
» Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic

Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.

Connect with CNBC News Online
Get the latest news: http://www.cnbc.com/
Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC
Follow CNBC News on Facebook:
Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC
Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC

#CNBC
#CNBC TV